Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 8,279 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Healthy Nutrition, Healthy Diet
Interventions: Carotenoid Intake, Serum carotenoid concentrations; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 3 Months to 24 Months
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Inflammation, Normal Controls, Metabolic Disease
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Age Related Macular Degeneration
Interventions: aflibercept 2.0 mg; Drug
Lead sponsor: David M. Brown, M.D.; Other
Eligibility: 50 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Age Related Macular Degeneration
Interventions: ranibizumab, bevacizumab; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 50 Years and older
Enrollment: 1,208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 59
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 50 more

Conditions: Autism Spectrum Disorder
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Up to 6 Months
Enrollment: 344 participants
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hearing Loss, Sensorineural
Interventions: MED-EL SYNCHRONY PIN Cochlear Implant, Cochlear Implant; Device · Other
Lead sponsor: Med-El Corporation; Industry
Eligibility: 7 Months to 5 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 8
States / cities: Oakland, California • Miami, Florida • Chicago, Illinois + 5 more

Conditions: Breast Cancer, Aging, Physical Activity
Interventions: Walk with Ease Program; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 65 Years and older · Female only
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions: aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22, aH5N6c on Day 22, aH5N8c on Day 202; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Cullman, Alabama • Lilburn, Georgia • Norcross, Georgia + 6 more

Conditions: Healthy Volunteers
Interventions: Prolon diet; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 70 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Body Composition, Circumference Measurements, Tissue Thickness Measurements
Interventions: Body Measurements, Whole Body DXA Scan, Bioelectrical Impedance Analysis (BIA), add name here; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 10 Years to 80 Years
Enrollment: 421 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Hematologic Diseases, Hematologic Malignancy, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
Interventions: CliniMACS, Bone Marrow Transplant, Hyperfractionated Total Body Irradiation, Thiotepa, Cyclophosphamide, Busulfan, Melphalan, Fludarabine; Device · Procedure · Drug
Lead sponsor: Baptist Health South Florida; Other
Eligibility: Up to 74 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cystic Fibrosis
Interventions: VX-561, IVA, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 30
States / cities: Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 25 more

Conditions: HIV, HIV Infections
Interventions: DTG/3TC; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 50 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 24
States / cities: Phoenix, Arizona • Bakersfield, California • Palm Springs, California + 21 more

Conditions: Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: imatinib mesylate, paclitaxel; Drug
Lead sponsor: University of Washington; Other
Eligibility: 70 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Albuquerque, New Mexico • Seattle, Washington

Conditions: Respiratory Distress Syndrome
Interventions: MIST surfactant; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: Up to 48 Hours
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Neovascularization, Choroidal, Macular Degeneration, Age-Related
Interventions: Faricimab, Ranibizumab, Sham Procedure; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 25
States / cities: Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 22 more

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: ADZENYS XR-ODT, Placebo Oral Tablet; Drug
Lead sponsor: Aytu BioPharma, Inc.; Industry
Eligibility: 4 Years to 5 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Status Asthmaticus
Interventions: Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC), Airlife Sidestream High Efficiency Nebulizer; Device
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 12 Months to 18 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Spinal and Bulbar Muscular Atrophy, Kennedys Disease, Motor Neuron Disease
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: trivalent Influenza vaccine (TIV); Biological
Lead sponsor: Emory University; Other
Eligibility: 25 Years and older
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Healthy Volunteers
Interventions: Darifenacin, Oxybutynin, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 60 Years and older
Enrollment: 150 participants
Timeline: 2005
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Contraception
Interventions: LNG20, Mirena; Drug
Lead sponsor: Medicines360; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 1,910 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2021
U.S. locations: 25
States / cities: Phoenix, Arizona • Palo Alto, California • San Francisco, California + 22 more

Conditions: Submacular Hemorrhage, Wet Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions: Anti-VEGF, Hemorrhage displacement + Anti-VEGF; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Baylor Infant and Toddler Biomarker of Nutrition Study

Natural History of the Human Biological Response to Environmental Exposure and Injury

Study for Recalcitrant Age Related Macular Degeneration

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial

Genome Environment Microbiome and Metabolome in Autism Study

Expanded Indications in the MED-EL Pediatric Cochlear Implant Population

Impact of Physical Activity on Biomarker of Aging and Body Composition Among Breast Cancer Survivors Age 65 and Older

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

Multi-cycle Prolon Diet

Calibrate Samsung's BIA to Meseaure Body Composition

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Non Inferiority Trial Investigating Surfactants Administered Via MIST

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder

Effectiveness and Cost Study Comparing Two Ways to Deliver Albuterol for the Treatment of Asthma in the Hospital

Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)

Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly

Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over

A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration